Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Non-Small Cell Lung Cancer to Receive Immunotherapy

The use of programmed cell death 1 ligand 1 (PD‐L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD‐1) or PD‐L1 inhibitors in non‐small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra‐ and intertumoral heteroge...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical pharmacology and therapeutics 2016-09, Vol.100 (3), p.220-222
Hauptverfasser:	Mansfield, AS, Dong, H
Format:	Artikel
Sprache:	eng
Schlagworte:	B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - biosynthesis Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Immunohistochemistry Immunotherapy, Adoptive - methods Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - pathology Patient Selection Prognosis Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - biosynthesis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!